Rising cases of cancer coupled with rising awareness regarding the health of patients are attributable to the growth of non-small cell lung cancer market. Data Bridge Market Research analyses that the non-small cell lung cancer will exhibit a CAGR of around 10.91% for the forecast period of 2021-2028.
Rising cases of cancer coupled with rising awareness regarding the health of patients are attributable to the growth of non-small cell lung cancer market. Data Bridge Market Research analyses that the non-small cell lung cancer will exhibit a CAGR of around 10.91% for the forecast period of 2021-2028.
The Global Fiducial Markers Market is projected to grow from USD 108.3 million in 2020 to USD 140.6 million by 2026 at a CAGR of over 4.4% during the forecast period.
The major players in the Lung Cancer Drugs Market are Bristol-Myers Squibb Company, Merck & Co., F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc.....@@ https://bit.ly/3n9T1Xq
This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Biocept EntroGen Cynvenio Biosystems Exosome Diagnostics F. Hoffmann-La Roche Clearbridge BioMedics
Lung Cancer Surgery Market 2019 Analysis and Review of Lung Cancer Surgery Market by Product - Thoracoscope, Mediastinoscope, Bronchoscope, Robotic-assisted Thoracic Surgery System, Surgical Stapler, and Surgical Energy Instrument for 2019 - 2029
Big Market Research | Noninvasive Cancer Diagnostics and Technologies Market | Non-invasive diagnostic is a process of identifying the disease conditions with minimal incision in body during diagnosis. The global market for diagnostic/in-vitro diagnostics valued at $49.2 billion in 2012, which shows potential for market growth, especially in chronic diseases. Non-invasive cancer diagnostics is gaining importance over conventional diagnosis due to increase in incidences of chronic cancer such as breast cancer, and lung cancer. According to American Cancer Society, there were more than 1,660,290 new cases diagnosed in 2013.
Cancer occurs due to cell transformation where normal cells grow and multiply without control. The common cause of mortality and morbidity worldwide is lung cancer that is caused majorly due to smoking. Lung cancer is categorized into two types such as non-small cell lung cancer and small cell lung cancer.
The global oncology drugs market size was valued at $135,494.17 million in 2020, and is projected to reach $274,400.63 million by 2030, registering a CAGR of 7.5% from 2021 to 2030.
Global cancer profiling market size is expected to reach $20.35 Bn by 2028 at a rate of 11.0%, segmented as by technology, immunoassays, pcr (polymerized chain reaction), ngs (next-generation sequencing), microarrays, in-situ hybridization
The cancer stem cell therapy market is expected to witness market growth at a rate of 9.65% in the forecast period of 2021 to 2028 and is expected to reach USD 1,859.41 million by 2028. https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-stem-cell-therapy-market
According to the latest research report by IMARC Group, The global cancer biomarkers market size reached US$ 27.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 77.0 Billion by 2032, exhibiting a growth rate (CAGR) of 11.7% during 2024-2032. More Info:- https://www.imarcgroup.com/cancer-biomarkers-market
The growing number of clinical trials and the increasing adoption of immunoassay techniques are among the primary factors driving the cancer/tumor profiling market Get a PDF Sample for more detailed market insights: Visit the following link: https://www.imarcgroup.com/cancer-tumor-profiling-market E-mail: sales@imarcgroup.com Contact: +91-120-415-5099
The GCC Oncology/Cancer Drugs Market is projected to grow at a considerable CAGR during the forecast period, i.e., 2023-28. A comprehensive examination of the GCC Oncology/Cancer Drugs market has been conducted by Markntel Advisors
According to the latest research report by IMARC Group, The global cancer biomarkers market size reached US$ 24.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 53.7 Billion by 2028, exhibiting a growth rate (CAGR) of 12.95% during 2023-2028. More Info:- https://www.imarcgroup.com/cancer-biomarkers-market
The blockchain supply chain market size reached USD 271 million in 2020 and is expected to reach USD 14,180 million in 2028 and register a CAGR of 63.9% in 2028, according to latest analysis by Emergen Research. Steady market revenue growth can be attributed to increasing need of transparency in the supply chain, technological advancements in transactions in supply chain are factor driving rising focus on improving data security and maintaining records of transactions. In addition, this trend is expected to continue during the forecast period.
According to market research report "Cancer Diagnostics Market by Product (Consumables (Anitibodies, Probes), Instruments (Pathology Instruments, Imaging Instruments, Biopsy), Technology (IVD Testing), Application (Breast Cancer, Lung Cancer), End User (Hospitals) - Global Forecasts to 2026", published by MarketsandMarkets™, is projected to reach USD 26.6 billion by 2026 from USD 17.2 billion in 2021, at a CAGR of 11.5%. Growth of the cancer diagnostics market is driven mainly by increasing incidence of cancer and growth in the number of private diagnostic laboratories.
The Global Food Cold Chain Market is projected to reach USD 526.00 billion in 2027. Technological innovation is expected to drive growth in packaging, processing and storage of seafood products.
According to the latest research report by IMARC Group, The global cancer tumor profiling market reached a value of US$ 9.38 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 18.22 Billion by 2027 exhibiting a growth rate (CAGR) of 11.20% during 2022-2027. More Info:- https://www.imarcgroup.com/cancer-tumor-profiling-market
Cancer Supportive Care Products Market 2020 Analysis and Review: Cancer Supportive Care Products Market by Indication – Lung Cancer, Prostate Cancer, Melanoma et al for 2020-2030
This report focuses on the global Cancer Immunotherapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cancer Immunotherapy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
Fiducial markers is also called as fiducial, which can be defined as the object which placed in the viewing field of an imaging system, which can be utilized as a point of measure or reference and which also appears in the image formed. Fiducial markers are implanted for targeting and defining the lesions which are located in the soft tissues of chest, abdomen, pelvis, head, and neck.
According to Renub Research analysis China Biopsy Market will be USD 8.1 Billion by 2026. Forecast by Cancer Segment, Volume of Biopsy and Patient Diagnosed Numbers, Company Analysis. Follow the Link for More Information: https://www.renub.com/china-biopsy-market-p.php
Cancer Tissue Diagnostics Market: North America to Retain Its Dominance Throughout the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016 - 2026
Some of the leading companies operating in the market are: Abbott Laboratories Roche Thermo Fisher Scientific Inc. Siemens AG Bio Rad Laboratories Inc. Illumina, Inc. Koninklijke Philips N.V. Canon Medical Systems Corporation Agilent Technologies Inc.
A new market study based on the Cancer/Tumor Profiling Market designed from various sources which also include porter's five forces analysis research techniques to explore the new opening of the market for the period of 2019-2025. The study also interrogates and examines the information based on share, market size, growth path, and the latest trends to recognize the potential value of the market. And most importantly, the data on the current business scenario will also help players to understand the stakeholder strategies and discover the new opportunities which will help them to succeed in their way.
Some of the top companies operating in the GCC syringes and needles market are – Becton, Dickinson & Company, Nipro Corporation, Baxter International Inc., B. Braun, Terumo Corporation, Medtronic PLC., Smiths Group Inc., Abu Dhabi Medical Devices Company, SAAPP (FZC) LLC., and IBN Sina Medical Factory.
The global oncology biosimilars market is expected to grow from $2.88 billion in 2020 to $3.1 billion in 2021 at a compound annual growth rate (CAGR) of 7.6%.
In its latest edition of the study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for cancer diagnostics. The report tracks the global sales of cancer diagnostics in 20+ high-growth markets, along with analyzing the impact COVID-19 has had on cancer diagnosis services in general, and cancer diagnostics in particular.
The lung cancer genomic testing medicine market was valued at $1,262.0 million in 2020 and is expected to reach $3,279.8 million by 2031, growing at a CAGR of 8.97% during the forecast period 2021-2031.
Global Checkpoint Inhibitors Market by The Business Research Company is segmented as Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Melanoma https://bit.ly/3H3vfTZ
Global Antibody Drug Conjugates Market by The Business Research Company is segmented as Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor https://bit.ly/2Vqyrq7
Global Conjugated Monoclonal Antibodies Market by The Business Research Company is segmented as Adcetris, Kadcyla, Cleavable Linker, Non-cleavable Linker, Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumour, Others https://bit.ly/3bDloGs
The report "Companion Diagnostics Market by Product (Assays, Kits, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User (Pharma Companies, CROs), Region - Global Forecast to 2026", the global companion diagnostics market is projected to reach USD 9.9 billion by 2026 from USD 5.5 billion in 2021, at a CAGR of 12.6%.
In its new study, FMI offers insights about key factors driving demand for pulmonology devices. The study points toward single-use bronchoscopes being the most sought-after due to the Increasing adaption of single-use bronchoscopes in lung cancer. COPD by indication hold more than thirty percent market share, globally.
The growing prevalence of cancer-related diseases and the elevating geriatric population, which is more susceptible to such disorders, represent some of the key factors driving the tanespimycin market. Additionally, the escalating use of tanespimycin for the treatment of lung cancer, kidney tumor, pediatric acute lymphoblastic leukemia, HER-2-positive breast cancer, etc., is also contributing to the market growth. Read more: https://www.syndicatedanalytics.com/tanespimycin-production-cost-analysis-report
Rising need to increase agricultural productivity while minimizing environmental degradation and rising global food demand are key factors driving market revenue growth
The report on Computer Aided Detection Market by application (breast cancer, lung cancer, prostate cancer, liver cancer, bone cancer, cardiovascular and neurological applications and others), imaging modalities (magnetic resonance imaging, ultrasound imaging, x-ray imaging, mammography and others) trends analysis and forecasts up to 2023 studies the market sizes, key trends and opportunities in the main geographies such as North America, Europe, Asia-Pacific, Rest of the World. According to the report the Global Computer Aided Detection Market is projected to grow at a CAGR between 13.5% and 14.0% in terms of value over the period of 2016-2022. The growth in the world market is primarily driven by significant contribution by North America (Leading region) region to this market.
The growing number of clinical trials and the increasing adoption of immunoassay techniques are among the primary factors driving the cancer/tumor profiling market. Moreover, the launch of various favorable policies by government bodies across countries for introducing numerous innovative techniques to reduce the time taken for the detection and identification of tumors is further catalyzing the market growth For an Executive Summary of Finance Cloud Report Visit the following link: https://www.imarcgroup.com/cancer-tumor-profiling-market E-mail: sales@imarcgroup.com Contact: +91-120-415-5099
Several factors have been instrumental in propelling the rapid growth of the oncology molecular diagnostics market in the Asia-Pacific region. The increasing prevalence of various types of cancer, coupled with the growing demand for advanced diagnostic tools, has fueled the need for more accurate and efficient molecular diagnostic techniques. Moreover, the rising awareness among patients and healthcare professionals about the benefits of early cancer detection has further catalyzed the adoption of molecular diagnostic solutions. Know More- https://www.alliedmarketresearch.com/asia-pacific-oncology-molecular-diagnostics-market-A06287
The major players in the community oncology services market are Community Care Physicians P.C., Nebraska Cancer Specialists, US Oncology, Inc, Tufts Medical Center... @ @ https://bit.ly/38jwLRM
The Global Solid Tumor Testing Market size is projected to grow at a CAGR of around 8.0% during the forecast period, 2023-28. In recent years, genomic analysis has impacted the diagnosis, prognostication, monitoring, and treatment decision-making for different solid tumors.
What Is Popcorn Lung? If you are reading this, it's likely that you have heard of "popcorn lung" - this is a serious lung disease caused by the chemical diacetyl. Read on to learn more about popcorn lung symptoms, causes, and treatments.
The global interventional oncology market size is projected to reach USD 2.9 billion by 2026 from USD 1.9 billion in 2020, at a CAGR of 6.8% during the forecast period. The major factors driving the growth of this market include the rapidly growing geriatric population and the subsequent increase in the prevalence of associated diseases; rising preference for minimally invasive procedures; technological advancements in interventional oncology modalities; and increasing investments, funds, and grants by public-private organizations.
Research Beam added report on “Global Radiotherapy Market 2015 - 2022”. Global Radiotherapy Market is estimated to be $6.1 billion in 2014 with CAGR of 6.65% is expected to reach $10.2 billion by 2022. The global radiotherapy market is a widely growing sector in recent years and is driven by factors such as increasing number of cancer patients and untapped market in some emerging countries. However factors such as expensive treatments, adequate infrastructure and adequate skills and training are hampering the market growth. The external beam radiation therapy is the largest segment of the Radiotherapy market followed by internal beam radio therapy. Enquiry @ http://www.researchbeam.com/global-radiotherapy-outlook-2014-2022-market/enquire-about-report